Chemotherapy (chemo) rechallenge in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC who discontinued 1L osimertinib (osi) + platinum–pemetrexed (plat–pem) due to progression (PD): FLAURA2 exploratory analysis

This presentation explores the outcomes of reusing chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer after disease progression on initial treatment. It highlights patterns of treatment rechallenge, patient characteristics, and survival outcomes across different therapy approaches. The findings suggest that chemotherapy rechallenge remains a relevant option in subsequent treatment strategies.